Verrica CEO to Present April 15 at Needham Conference, Spotlighting YCANTH® and VP-315
Verrica Pharmaceuticals’ CEO Jayson Rieger will present at the 25th Annual Needham Virtual Healthcare Conference on April 15 at 3:00pm ET, with a live webcast available and replay for 90 days. The company will highlight its FDA-approved YCANTH® for molluscum contagiosum and the VP-315 license deal with Lytix Biopharma.
1. Conference Participation
Verrica’s President and CEO Jayson Rieger will present at the 25th Annual Needham Virtual Healthcare Conference on April 15 at 3:00pm ET, marking the company’s engagement with analysts and institutional investors.
2. Webcast Details
Investors can access the live presentation via webcast on the company’s website, with a replay available for 90 days following the event in the Presentations & Events section.
3. Product Pipeline Overview
Verrica will outline progress on YCANTH®, the first FDA-approved treatment for molluscum contagiosum affecting approximately 6 million Americans, its development program for common warts, and the worldwide license agreement with Lytix Biopharma for VP-315 targeting non-melanoma skin cancers.